(Q48075919)

8 February 2018

title

Treatment of advanced thyroid cancer with axitinib: Phase 2 study with pharmacokinetic/pharmacodynamic and quality-of-life assessments (English)

1 reference

8 February 2018

1 reference

1 reference

1 reference

1 reference

1

1 reference

8 February 2018

Barbara Jarząb

6

object named as

Barbara Jarzab

1 reference

8 February 2018

Lisa Licitra

2

0 references

Ezra E Cohen

15

object named as

Ezra E W Cohen

1 reference

8 February 2018

author name string

Laura Agate

3

1 reference

8 February 2018

Sai-Hong I Ou

4

1 reference

8 February 2018

Andree Boucher

5

1 reference

8 February 2018

Shukui Qin

7

1 reference

8 February 2018

Madeleine A Kane

8

1 reference

8 February 2018

Lori J Wirth

9

1 reference

8 February 2018

Connie Chen

10

1 reference

8 February 2018

Sinil Kim

11

1 reference

8 February 2018

Antonella Ingrosso

12

1 reference

8 February 2018

Yazdi K Pithavala

13

1 reference

8 February 2018

Paul Bycott

14

1 reference

8 February 2018

language of work or name

English

0 references

publication date

20 May 2014

1 reference

8 February 2018

published in

Cancer

1 reference

8 February 2018

volume

120

1 reference

8 February 2018

issue

17

1 reference

8 February 2018

page(s)

2694-2703

1 reference

8 February 2018

International patterns and trends in thyroid cancer incidence, 1973-2002

cites work

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28766

Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28766

Thyroid cancer incidence and survival in the national cancer institute surveillance, epidemiology, and end results race/ethnicity groups

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28766

Cancers with increasing incidence trends in the United States: 1999 through 2008.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28766

Long-term outcome of 444 patients with distant metastases from papillary and follicular thyroid carcinoma: benefits and limits of radioiodine therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28766

Efficacy of pazopanib in progressive, radioiodine-refractory, metastatic differentiated thyroid cancers: results of a phase 2 consortium study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28766

Phase II study of daily sunitinib in FDG-PET-positive, iodine-refractory differentiated thyroid cancer and metastatic medullary carcinoma of the thyroid with functional imaging correlation

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28766

Axitinib is an active treatment for all histologic subtypes of advanced thyroid cancer: results from a phase II study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28766

Cabozantinib in progressive medullary thyroid cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28766

Phase II trial of sorafenib in advanced thyroid cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28766

Phase II trial of sorafenib in metastatic thyroid cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28766

Activity of XL184 (Cabozantinib), an oral tyrosine kinase inhibitor, in patients with medullary thyroid cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28766

Vandetanib in locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 2 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28766

Phase II study of safety and efficacy of motesanib in patients with progressive or symptomatic, advanced or metastatic medullary thyroid cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28766

Motesanib diphosphate in progressive differentiated thyroid cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28766

Vandetanib in patients with locally advanced or metastatic medullary thyroid cancer: a randomized, double-blind phase III trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28766

Regional approaches to the management of patients with advanced, radioactive iodine-refractory differentiated thyroid carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28766

Clinical, safety, and economic evidence in radioactive iodine-refractory differentiated thyroid cancer: a systematic literature review

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28766

Nonclinical antiangiogenesis and antitumor activities of axitinib (AG-013736), an oral, potent, and selective inhibitor of vascular endothelial growth factor receptor tyrosine kinases 1, 2, 3.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28766

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28766

Axitinib in metastatic renal cell carcinoma: results of a pharmacokinetic and pharmacodynamic analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28766

Axitinib versus sorafenib as second-line treatment for advanced renal cell carcinoma: overall survival analysis and updated results from a randomised phase 3 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28766

Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28766

Quality of life in patients with thyroid cancer compared with the general population

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28766

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28766

Quality of life after thyroid cancer: an assessment of patient needs and preferences for information and support.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28766

Analysis of the efficacy and toxicity of sorafenib in thyroid cancer: a phase II study in a UK based population

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28766

Vascular endothelial growth factor gene and protein: strong expression in thyroiditis and thyroid carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28766

inferred from DOI database lookup

7 January 2021

based on heuristic

Diastolic blood pressure as a biomarker of axitinib efficacy in solid tumors

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28766

inferred from DOI database lookup

7 January 2021

based on heuristic

Is there room for improvement in adverse event reporting in the era of targeted therapies?

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28766

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1002/CNCR.28766

1 reference

8 February 2018

1 reference

8 February 2018